CanSino Biologics Inc. (HKG:6185)
34.60
+0.30 (0.87%)
Jun 6, 2025, 4:08 PM HKT
CanSino Biologics Revenue
CanSino Biologics had revenue of 137.16M CNY in the quarter ending March 31, 2025, with 20.02% growth. This brings the company's revenue in the last twelve months to 869.22M, up 134.41% year-over-year. In the year 2024, CanSino Biologics had annual revenue of 846.34M with 137.01% growth.
Revenue (ttm)
869.22M CNY
Revenue Growth
+134.41%
P/S Ratio
12.90
Revenue / Employee
786.62K CNY
Employees
1,105
Market Cap
12.02B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 846.34M | 489.25M | 137.01% |
Dec 31, 2023 | 357.08M | -677.51M | -65.49% |
Dec 31, 2022 | 1.03B | -3.27B | -75.94% |
Dec 31, 2021 | 4.30B | 4.27B | 17,174.82% |
Dec 31, 2020 | 24.89M | 22.61M | 990.05% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.53B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |
Sino Biopharmaceutical | 30.72B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
CanSino Biologics News
- 5 weeks ago - CanSino Biologics CEO on earnings, business outlook, and international partnerships - CNBC
- 2 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 2 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 3 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 3 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 3 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 3 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 3 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire